Cadinha & Co. LLC Has $434,000 Position in Stryker Co. (NYSE:SYK)

Cadinha & Co. LLC raised its stake in Stryker Co. (NYSE:SYK) by 9.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206 shares of the medical technology company’s stock after acquiring an additional 106 shares during the period. Cadinha & Co. LLC’s holdings in Stryker were worth $434,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Oak Ridge Investments LLC grew its stake in Stryker by 6.3% during the fourth quarter. Oak Ridge Investments LLC now owns 29,186 shares of the medical technology company’s stock worth $10,508,000 after buying an additional 1,731 shares in the last quarter. Aaron Wealth Advisors LLC boosted its position in shares of Stryker by 8.4% during the 4th quarter. Aaron Wealth Advisors LLC now owns 2,903 shares of the medical technology company’s stock worth $1,045,000 after acquiring an additional 225 shares in the last quarter. Moss Adams Wealth Advisors LLC raised its position in Stryker by 6.9% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 803 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 52 shares in the last quarter. TruWealth Advisors LLC lifted its stake in Stryker by 7.1% during the fourth quarter. TruWealth Advisors LLC now owns 1,927 shares of the medical technology company’s stock worth $694,000 after purchasing an additional 128 shares during the last quarter. Finally, HB Wealth Management LLC boosted its holdings in shares of Stryker by 2.4% in the 4th quarter. HB Wealth Management LLC now owns 9,476 shares of the medical technology company’s stock valued at $3,412,000 after purchasing an additional 221 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by corporate insiders.

Stryker Stock Performance

NYSE:SYK opened at $383.91 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20. The company has a 50 day simple moving average of $375.51 and a two-hundred day simple moving average of $358.81. The company has a market capitalization of $146.35 billion, a PE ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 earnings per share. Research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s payout ratio is currently 36.01%.

Analyst Ratings Changes

Several analysts recently weighed in on SYK shares. Truist Financial upped their price objective on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Evercore ISI upped their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. UBS Group raised their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Robert W. Baird upped their price target on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.